Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells
Background CFTR c.3233 T>C (p.(Phe1078Ser); F1078S) is an ultra-rare missense variant for which clinical and functional data are very limited. As theratyping is an important experimental component of precision theranostics in cystic fibrosis (CF), we investigated the molecular and functional consequences of F1078S and its responsiveness to CFTR modulators. Methods F1078S-CFTR was transiently expressed in human bronchial epithelial CFBE41o − cells using a GFP-tagged CFTR construct. CFTR protein processing and biosynthesis were assessed by Western blotting, while channel function was evaluated by Ussing chamber recordings. The effects of elexacaftor and vanzacaftor, each combined with tezacaftor were investigated. F1078 was mapped on the three-dimensional (3D) structure of human CFTR. Results F1078 is located at the ICL1/ICL4 interface, near the “pocket” left vacant by F508 in patients with F508del (ICL4/NBD1 interface). F1078S-CFTR exhibited defective protein processing, as evidenced by the absence of the mature C-band, and showed no detectable CFTR channel function. Treatment of F1078S-expressing CFBE41o − cells with elexacaftor/tezacaftor or vanzacaftor/tezacaftor restored CFTR protein processing and rescued channel function. Conclusion F1078S located in a critical region for folding and assembly, exhibits a CFTR processing/trafficking defect consistent with a class II molecular phenotype, together with impaired channel function. Both defects were rescued by elexacaftor/tezacaftor and vanzacaftor/tezacaftor, providing functional evidence of CFTR modulator responsiveness for this ultra-rare variant. These findings highlight the potential of theratyping to inform individualized therapeutic strategies for patients carrying rare CFTR variants.
Authors
- Hugues Abriel (ORCID: https://orcid.org/0000-0003-0465-5138)
- Louise Damy
- C. Barrault
- Matthieu Régnacq (ORCID: https://orcid.org/0000-0002-5932-4398)
- Frédéric Becq (ORCID: https://orcid.org/0000-0003-3915-0973)
- Sandra Mirval
- Nada El Makhzen (ORCID: https://orcid.org/0009-0001-4786-9913)
- Isabelle Callebaut (ORCID: https://orcid.org/0000-0003-3124-887X)
- Mael Estivalezes
Institutions
- University of Bern (CH)
- Centre National de la Recherche Scientifique (FR)
- Université de Poitiers (FR)
- Sorbonne Université (FR)
- Institut de minéralogie, de physique des matériaux et de cosmochimie (FR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fphar.2026.2007119
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00